Latest Expert Opinions

Signal
Opinion
Expert
TOP PICK
TOP PICK
December 28, 2016

This had a patent cliff with Wyatt a couple of years ago, which had a lot of promising new drugs. They have a huge amount of assets overseas in cash, which they would love to bring back, but taxation rates to bring that back are very, very high. Under the Trump administration, it is expected that that is going to change and the tax rate is going to plummet, making a lot of sense for US drug companies to bring money back in, which they can use for share buybacks, acquisitions or pumping up R&D. Dividend yield of 3.96%. (Analysts’ price target is $37.42.)

Pfizer Inc (PFE-N)
December 28, 2016

This had a patent cliff with Wyatt a couple of years ago, which had a lot of promising new drugs. They have a huge amount of assets overseas in cash, which they would love to bring back, but taxation rates to bring that back are very, very high. Under the Trump administration, it is expected that that is going to change and the tax rate is going to plummet, making a lot of sense for US drug companies to bring money back in, which they can use for share buybacks, acquisitions or pumping up R&D. Dividend yield of 3.96%. (Analysts’ price target is $37.42.)

Norman Levine
Managing Director, Portfolio Management Corp
Price
$32.350
Owned
Yes